Related Experiment Video

Updated: Sep 13, 2025

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.4K

HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease

Siyi Yang1,2, Yidong Sun1,2, Wei Yu1,2

  • 1Institute of Biochemistry, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Xiasha High-Tech Zone No.2 Road, Hangzhou 310018, China.

Cells
|July 25, 2025
PubMed

Insights

Histone deacetylases (HDACs) and their inhibitors (HDACis) are crucial in cardiovascular health and disease. Understanding their role in protein modifications offers new therapeutic avenues for cardiovascular diseases (CVD).

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Cardiovascular Medicine

Background:

  • Cardiovascular diseases (CVD) pose a significant global health threat.
  • Post-translational modifications regulate protein function and are vital for cardiovascular homeostasis.
  • HDACs are key epigenetic regulators involved in post-translational modifications linked to CVD pathogenesis.

Purpose of the Study:

  • To systematically review the role of HDACs and HDAC inhibitors (HDACis) in post-translational modifications relevant to cardiovascular diseases.
  • To explore the therapeutic potential of HDACis for treating CVD.
  • To identify future research directions concerning HDACs, HDACis, and cardiovascular health.

Main Methods:

  • Literature review of studies on HDACs, HDACis, post-translational modifications, and cardiovascular diseases.
  • Systematic summary of the mechanisms of action of HDACs and HDACis.
  • Analysis of the link between HDACs, HDACis, and CVD pathogenesis.

Main Results:

  • HDACs catalyze histone deacetylation, impacting gene expression and cardiovascular function.
  • HDACis demonstrate potential as a novel therapeutic strategy for cardiovascular diseases.
  • Post-translational modifications mediated by HDACs are closely implicated in the development of various cardiovascular conditions.

Conclusions:

  • HDACs and their inhibitors play a significant role in the molecular mechanisms underlying cardiovascular diseases.
  • Targeting HDACs with HDACis presents a promising approach for novel CVD treatments.
  • Further research into the intricate relationship between HDACs, HDACis, and cardiovascular pathophysiology is warranted.

Keywords:
HDACHDACicardiovascular disease (CVD)post-translational modification (PTM)

More Related Videos

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins08:12

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins

Published on: January 8, 2018

11.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
58
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
888
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
827
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K